Prophylactic Treatment of Migraine with Beta-Blockers and Riboflavin: Differential Effects on the Intensity Dependence of Auditory Evoked Cortical Potentials
[en] OBJECTIVE: To investigate the influence of different pharmacological treatments on the intensity dependence of auditory evoked cortical potentials in migraineurs. BACKGROUND: Between attacks, patients with migraine show abnormalities in cortical information processing and decreased brain mitochondrial energy reserve. Both are most probably relevant for migraine pathogenesis, and they could be differentially modified by prophylactic drug therapy. Design.-The intensity dependence of the auditory evoked cortical potentials is, on average, increased in migraine. We have studied this intensity dependence in 26 patients before and after a 4-month period of prophylaxis with beta-blockers (n = 11, all migraine without aura; metoprolol or bisoprolol) or riboflavin (n = 15, migraine without aura: 13, migraine with aura: 2). Recordings were performed at least 3 days before or after an attack. RESULTS: After the treatment with beta-blockers, the intensity dependence of the auditory evoked cortical potentials was significantly decreased (before: 1.66+/-1.02 microV/10 dB; after: 0.79+/-1.06 microV/10 dB, P=.02). The decrease in intensity dependence was correlated significantly with clinical improvement (r = .69, P = .02). There was no change in intensity dependence after riboflavin treatment (before: 1.80+/-0.81 microV/10 dB; after: 1.56+/-0.83 microV/10 dB, P = .39), although the majority of patients showed improvement. CONCLUSIONS: These results confirm that beta-blockers and riboflavin act on two distinct pathophysiological mechanisms. Combining both treatments might enhance their efficacy without increasing central nervous system side effects.
Disciplines :
Neurology Neurosciences & behavior
Author, co-author :
Sandor, P. S.
Afra, J.
Ambrosini, A.
Schoenen, Jean ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie
Language :
English
Title :
Prophylactic Treatment of Migraine with Beta-Blockers and Riboflavin: Differential Effects on the Intensity Dependence of Auditory Evoked Cortical Potentials
Proietti Cecchini A, Áfra J, Schoenen J. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of CNS serotonin transmission in man: demonstration of a central effect for the 5-HT1B/1D agonist zolmitriptan (311C90, Zomig®). Cephalalgia. 1997;17:849-854.
Schoenen J. Pathogenesis of migraine: the biobehavioural and hypoxia theories reconciled. Acta Neurol Belg. 1994;94:79-86.
Wang W, Timsit-Berthier M, Schoenen J. Intensity dependence of auditory evoked potentials is pronounced in migraine: an indication of cortical potentiation and low serotonergic neurotransmission? Neurology. 1996;46:1404-1409.
Áfra J, Proietti Cecchini A, De Pasqua V, Albert A, Schoenen J. Visual evoked potentials during long-lasting pattern-reversal stimulations in migraine. Brain. 1998;121:233-241.
Welch KMA, Levine SR, D'Andrea G, et al. Preliminary observations on brain energy metabolism in migraine studied by in vivo 31-phosphorus NMR spectroscopy. Neurology. 1989;39:538-541.
Barbiroli B, Montagna P, Cortelli P, et al. Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology. 1992;42:1209-1214.
Montagna P, Cortelli P, Monari L, et al. 31P-Magnetic resonance spectroscopy in migraine without aura. Neurology. 1994;44:666-668.
Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology. 1998;50:466-470.
International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
Schoenen J. Cortical electrophysiology in migraine and possible pathogenetic implications. Clin Neurosci. 1998;5:10-17.
Schoenen J. Beta-blockers and the central nervous system. Cephalalgia. 1986; 6(suppl 5):47-54.
Hegerl U, Juckel G. Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: a new hypothesis. Biol Psychiatry. 1993;33:173-187.
Lazarova-Bakarova MB, Stancheva S, Petkova B, et al. Effects of α-adrenoceptor blocker pindolol, calcium antagonist verapamil and their combination of retention in step-down and shuttle-box-trained rats and on brain biogenic monoamines. J Physiol Paris. 1997;91:301-305.
McAinsh J, Cruickshank JM. Beta-blockers and central nervous system side effects. Pharmacol Ther. 1990;46:163-167.
Dahlöf C, Dimenäs E. Side effects of beta-blockade treatment as related to the central nervous system. Am J Med Sci. 1990;299:236-244.
Penn AMW, Lee JWK, Thuillier P, et al. MELAS syndrome with mitochondrial tRNALeu(UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology. 1992;42:2147-2152.
Antozzi D, Garavaglia B, Mora M, et al. Late-onset riboflavin responsive myopathy with combined multiple acyl coenzyme: a dehydrogenase and respiratory chain deficiency. Neurology. 1994;44:2153-2158.